cas 3056-18-6|| where to buy (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate

Nombre del producto:(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate

IUPAC Name:[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2,6-dichloro-9H-purin-9-yl)oxolan-2-yl]methyl acetate

Unidad de embalaje	Stock disponible	Precio($)
CM138799-5g	in stock	ƞƞŭ
CM138799-25g	in stock	ȀŭŔ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3056-18-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :3056-18-6; Fórmula molecular:C16H16Cl2N4O7; Punto de fusión:-; Código de sonrisas:O=C(OC[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](N2C=NC3=C(Cl)N=C(Cl)N=C23)O1)C; Densidad:

: Número de catálogo:CM138799; Peso molecular:447.23; Punto de ebullición:555.3°C at 760 mmHg; Nº Mdl:MFCD02093101; Almacenamiento:Keep in inert atmosphere, store at 2-8°C.

: Nucleosides and Nucleotides; Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.; nucleoside manufacturer; As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: Nucleosides; Nucleosides are glycosylamines that can be thought of as nucleotides without a phosphate group. A nucleoside consists simply of a nucleobase (also termed a nitrogenous base) and a five-carbon sugar (ribose or 2'-deoxyribose).

: Namodenoson; Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Namodenoson granted Orphan Drug and Fast track status from the FDA. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.